KMT2A and acute myeloid leukemia: Overall, these findings support further in vivo testing and development of these MI-based combinations to not only improve the efficacy of ziftomenib, but also to undermine resistance to ziftomenib monotherapy in AML with MLL1-r or mtNPM1 that is encountered in the clinic.